Compounded Infliximab
Introduction
The Compounded Infliximab Framework, managed by the East of England NHS, is a public sector procurement route dedicated to the provision of compounded infliximab, a crucial medication used in the treatment of various autoimmune conditions such as rheumatoid arthritis and Crohn's disease. This framework is not a Dynamic Purchasing System (DPS) and is set to conclude on 1st February 2025. Its primary purpose is to ensure a streamlined supply chain for compounded infliximab, enabling efficient and effective patient care within NHS facilities.
Context & Use Case
Infliximab is a monoclonal antibody medication that requires careful preparation to ensure its safety and efficacy for patient use. The framework facilitates the procurement of infliximab from manufacturers, where it is then compounded in a sterile environment, and prepared in infusion-ready devices for clinical administration. Contracting authorities, primarily NHS Trusts, utilise this framework to secure reliable access to infliximab, thereby supporting their mandate to deliver timely and quality healthcare services. The division into three parts based on brands—Inflectra, Remicade, and Remsima—allows for flexibility and choice depending on clinical preference or specific patient needs.
Scope of Services
1. Procurement of infliximab from approved pharmaceutical manufacturers. 2. Sterile compounding of infliximab to ensure it meets clinical standards for safety and effectiveness. 3. Preparation of infliximab in infusion-ready devices for seamless clinical use. 4. Provision across multiple brands (Inflectra, Remicade, Remsima) to accommodate varying clinical requirements. 5. Ongoing quality assurance and compliance with NHS pharmaceutical standards.
Who Can Apply
Suppliers suitable for this framework are those with the capability to handle and compound pharmaceuticals in a sterile environment, ensuring adherence to stringent NHS quality and safety standards. Pharmaceutical companies, compounding pharmacies, and specialised medical supply firms with a focus on immunology and biologics are prime candidates. As this is not a dynamic purchasing system, the application is closed post-award, and new suppliers cannot join during its tenure.
Buyer Benefits
For public sector buyers, using this framework offers several advantages. It ensures compliance with NHS procurement policies and provides a reliable and quality-assured supply of infliximab. Additionally, the framework enables a quicker route to market, reducing the lead time for healthcare providers to access necessary medications. This approach also fosters competition among suppliers, potentially driving down costs and improving service levels.
Lots
Not applicable
Next Steps
Suppliers interested in participating should thoroughly review the framework's requirements and ensure they meet the necessary qualifications and compliance standards. Direct contact with the framework owner, the East of England NHS, is advisable for more detailed information and guidance on potential opportunities within this framework.
How Biddable Can Help
Biddable supports suppliers by providing comprehensive insights into public sector frameworks like the Compounded Infliximab Framework. Our services are designed to help suppliers discover relevant opportunities, prepare effectively for participation, and maintain visibility over potential contracts in their pipeline. By offering a clear understanding of the public procurement landscape, we aid suppliers in making informed decisions that align with their business capabilities and objectives.